Pharmaceutical - GlaxoSmithKline


Current filters:


Popular Filters

401 to 420 of 420 results

GlaxoSmithKline launches $50 million Life Sciences Innovation Fund in Canada


UK pharma giant GlaxoSmithKline (LSE: GSK) has launched the GSK Canada Life Sciences Innovation Fund,…

FinancialGlaxoSmithKlineNorth AmericaPharmaceuticalResearch

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018


The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK


US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

GlaxoSmithKline finalizes $3 billion deal with US government over marketing practices


UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has reached an agreement in principle…

AvandiaFinancialGlaxoSmithKlineLegalNorth AmericaPharmaceutical

Hepatitis B vaccines market forecast to show moderate growth until 2018


The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast…

Anti-viralsGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalVaccines

Important decision for the biotech industry from UK Supreme Court


The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

GlaxoSmithKline posts solid 3rd-qtr results, in line with expectations; joins WIPO scheme


UK pharma giant GlaxoSmithKline (LSE: GSK) seems to have overcome some of its problems, such exceptional…


Benlysta to drive lupus drug market to $2.1 billion in 2020


Driven primarily by the launch and uptake of Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseases

Cancer vaccines market set to see change, will grow to over $9 billion by 2018


The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news


UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports


Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Epizyme earns $4 million pre-clinical milestone from GSK under novel HMT therapeutics alliance


Privately-held US biotech startup Epizyme says it has achieved a pre-clinical milestones in its alliance…


ViiV Healthcare announces 16 new grantees for 2011/2012 to prevent mother-to-child HIV transmission


ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsFinancialGlaxoSmithKlineHealthcarePfizerPharmaceuticalRest of the WorldViiV Healthcare

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions


The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix


An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus…

CervarixEuropeGardasilGlaxoSmithKlineMerck & CoPharmaceuticalPricingVaccines

Medicines Australia starts new Code of Conduct review


Pharma trade group Medicines Australia has commenced a Review of its Code of Conduct and invites public…

Asia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalRegulation

ViiV Healthcare withdraws applications of once-daily Celsentri/Selzentry


UK-based ViiV Healthcare, a global specialist HIV company established in November 2009 by UK pharma giant…

Anti-viralsCelsentriEuropeGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationSelzentryViiV Healthcare

Amgen’s Prolia increases bone mineral density over eight; new indications approved


The world’s largest biotechnology firm, USA-based Amgen (Nasdaq: AMGN) says that new long-term data…


401 to 420 of 420 results

Back to top